House Energy and Commerce Committee Republicans on Monday (Aug. 29) asked FDA officials whether approval criteria is to blame in part for the lack of generic competition to Mylan Pharmaceuticals' EpiPen. E&C Chair Fred Upton (R-MI) and subcommittee chairs Tim Murphy (R-PA) and Joe Pitts (R-PA) made the inquiry on the same day Mylan announced it plans to sell a generic version of its EpiPen for $300 per two-pack carton, which is about half the price of EpiPen, in an...